Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Mismatch Repair Proficient (pMMR) Recurrent/Unresectable Endometrial Carcinoma

The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.

Study Overview

• Status: Recruiting
• Conditions: Recurrent Endometrial Carcinoma; Unresectable Endometrial Carcinoma
• Intervention / Treatment: Drug: Lenvatinib; Drug: Pembrolizumab; Radiation: Hypofractionated External Beam Radiation Therapy; Radiation: High-Dose Rate (HDR) Brachytherapy

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Aaron H Wolfson, MD, FACR; Phone Number: 954-698-3680; Email: awolfson@med.miami.edu

Study Locations

• United States
  • Florida
    • Miami, Florida, United States, 33136
      • Recruiting
      • University of Miami
      • Contact: Aaron H Wolfson, MD, FACR; Phone Number: 954-698-3680; Email: awolfson@med.miami.edu
      • Principal Investigator: Aaron H Wolfson, MD, FACR
      • Principal Investigator: Matthew Sclhumbrecht, MD, MPH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Biopsy-proven recurrent pMMR EC following surgery alone or de novo unresectable pMMR EC for whom EBRT has been determined as an appropriate therapeutic approach. Eligible tumor histologies include the following: endometrioid adenocarcinoma, adenocarcinoma with squamous differentiation, mucinous, mixed carcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, serous adenocarcinoma, and uterine carcinosarcoma histologies as determined by tissue from an archival sample or newly obtained core or excisional biopsy of a tumor lesion. For patients with recurrent disease greater than 12 months (>12 months), a fresh biopsy must be obtained.
2. Measurable disease of at least 1.0 cm in size defined by RECIST 1.1 on imaging studies with at least one (1) site located in the pelvis and/or vagina without any foci of extra-pelvic disease (including the para-aortic region or inguinal-femoral lymph nodes).
3. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky score ≥50).
4. Patients must have pMMR tumor subtype(s).

5. Patients must have normal organ and marrow function as defined below:

   1. Absolute neutrophil count (ANC) ≥1,500 cells/mm³
   2. Platelets ≥100,000 cells/mm³
   3. Hemoglobin ≥9.0 g/dL
   4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatine clearance (CrCl) ≥ 40 mL/min or Measured or calculated a creatinine clearance glomerular filtration rate (GFR) can also be used in place of creatinine
   5. Serum total bilirubin <1.0 ULN
   6. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine transaminase (ALT) serum glutamic-pyruvic transaminase (SGPT) Aminotransferase (AST and ALT) ≤ 2.5 x ULN or 5 X ULN for patients with liver metastases
   7. Albumin ≥2.5 mg/dL CrCl should be calculated per institutional standard.
6. Female participants of childbearing potential (those who have not been surgically sterilized or have not been without menses for >1 year) should be willing to use 2 methods of birth control at the same time or be surgically sterile or abstain from heterosexual activity for the course of the study and for at least 120 days after the last study dose.
7. Ability to understand and the willingness to sign a written informed consent document.
8. Prior treatment with lenvatinib, anti-programmed cell death protein 1 (anti-PD-1), anti-Programmed death-ligand 1 (anti-PD-L1) , or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways is allowed provided that the participant has not received any of these treatments within three weeks (+/- 3 days) of the first dose of study treatment.
9. Women age ≥18 years old.
10. Patients who have received prior adjuvant vaginal high dose rate (HDR) brachytherapy without EBRT following hysterectomy will be eligible as long as the cumulative Equivalent Dose at 2-Gy (EqD2) for external beam pelvic dose and vaginal HDR brachytherapy dose for the rectum and sigmoid colon is at most 70 Gy, for bowel at most 65 Gy, and for bladder at most 90 Gy.

Exclusion Criteria:

1. Patients who are currently in or have participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of study treatment.
2. Patients with Mismatch repair deficient (dMMR) and endometrial carcinomas.
3. Patients with dMMR and uterine carcinosarcomas.

4. Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

   EXCEPTION: Patients with previously treated brain metastases, including receiving prior brain irradiation, may participate provided they are stable (without evidence of progression by imaging for at least 3 months prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, are not using steroids for at least 28 days prior to study treatment, and have not received prior cranial irradiation for at least 3 months prior to study treatment.

5. Patients with a known additional malignancy that is progressing or requires active treatment. EXCEPTIONS include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
6. No prior external beam radiation therapy to the vagina, pelvis, and/or abdomen will be allowed.
7. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or other serious medical condition or social situations that in the judgement of the Investigator(s) would interfere or limit compliance with study requirements/treatments.
8. Receiving systemic steroid therapy or any other form of immunosuppressive therapy within 21 days prior to the first dose of study treatment. Note: Patients with active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs) and/or requiring replacement therapy (i.e., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
9. Evidence of interstitial lung disease or active, non-infectious pneumonitis.
10. Evidence of uncontrolled hypertension as documented in the patient's medical record.
11. Known psychiatric illness/condition or substance abuse disorders that in the judgement of the Investigator(s) would interfere with cooperation with requirements of the study.
12. Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the pre-screening or screening visit through 120 days after the last dose of study treatment.

13. Patients with uncontrolled human immunodeficiency virus (HIV) infection, which is defined as follows:

    1. Antiviral therapy treatment for <4 weeks AND
    2. Have an HIV viral load ≥400 copies/mL prior to enrollment.

14. Patients with uncontrolled hepatitis B virus (HBV) infection or who are chronic carriers of hepatitis B infection, which is defined as:

    1. Hepatitis B surface antigen reactive (HbsAg-positive), undetectable or low HBV DNA, and with normal ALT levels who are not on HBV therapy
    2. Individuals who have serologic evidence of a resolved prior HBV infection (ie, HBSAg-negative and anti-core hepatitis B antibody positive (anti-Hepatitis B core -positive)
15. Patients with active, untreated hepatitis C virus (HCV) infection or who have not completed their HCV antiviral regimen. Patients with a history of HCV infection may participate in this study if their HCV ribonucleic acid (RNA) level is below the limit of quantification.
16. Received live vaccine within 30 days prior to the first dose of study treatment.
17. Patient has active Mycobacterium tuberculosis infection (tuberculosis or TB).
18. A QT interval corrected for heart rate using Bazett's formula (QTcB) ≥ 480msec.
19. Patient receiving concurrent additional biologic therapy.
20. Patients with impaired decision-making capacity.
21. Patients who have not recovered from major surgery.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Lenvatinib, Pembrolizumab and Hypofractionated (HypoFx) External Beam Radiation Therapy (EBRT) Group; Participants in this group will receive a combination treatment of Lenvatinib, Pembrolizumab, and HypoFx Pelvic EBRT over a period of approximately 10 to 12 weeks: Lenvatinib self-administered daily starting on Day 1 of the study treatment period and continuing until the last dose of whole pelvic HypoFx EBRT is received.; Pembrolizumab administered on Day 1, 22 and 43.; Whole pelvic HypoFx EBRT beginning on Day 22. After receiving whole pelvic Hypo EBRT, participants will receive a boost course of radiation therapy using one of the following techniques: Pelvic boost HypoFx EBRT to be administered over a period of 1.5 to 2 weeks; OR; Vaginal HDR brachytherapy boost to be administered over a period of 2 to 3 weeks, depending on the lesion thickness; OR; Both pelvic boost HypoFx EBRT pelvic plus vaginal HDR brachytherapy boost. The overall radiation therapy treatment time for whole pelvic HypoFx RT and radiation boost treatments is approximately 7 weeks.

Drug: Lenvatinib; Lenvatinib will be self-administered orally (PO) by participants in a 3+3 escalation/de-escalation design. Participants will receive one of the following four dose levels: Dose level 1: 4 mg; Dose level 2: 8 mg; Dose level 3: 12 mg (Starting dose); Dose level 4: 16 mg; Other Names: Lenvima; Drug: Pembrolizumab; Pembrolizumab 200 mg will be administered intravenously (IV) once on Days 1, 22 and 43.; Other Names: Keytruda; Radiation: Hypofractionated External Beam Radiation Therapy; Whole pelvic HypoFx EBRT consisting of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 17.5 Gy, delivered to site(s) of gross disease of at least 1.0 cm in size.; Radiation: High-Dose Rate (HDR) Brachytherapy; Vaginal high-dose rate (HDR) brachytherapy administered per standard of care (SoC) techniques.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recommended Phase 2 Dose (RP2D) of Lenvatinib	The RP2D will be the highest dose of Lenvatinib that in combination with Pembrolizumab and Hypofractionated (HypoFx) pelvic External Beam Radiotherapy (EBRT) yields less than 2 Dose Limiting Toxicities (DLTs) in 6 patients.	Up to 12 weeks
Number of Participants Experiencing Treatment-Related Toxicity: Dose-Limiting Toxicities (DLTs)	The number of participants experiencing treatment-related DLTs will be reported. DLTs will be assessed by the treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.	Up to 12 weeks
Number of Participants Experiencing Treatment-Related Toxicity: Adverse Events (AEs)	The number of participants experiencing treatment-related adverse events (AEs) will be reported. AEs will be assessed by the treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.	Up to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	ORR is defined as the number of participants achieving a Complete Response (CR) or Partial Response (PR) to study therapy according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).	Up to 12 weeks
Number of Participants Experiencing Non-Treatment-Related Adverse Events	The number of participants experiencing non-treatment-related adverse events (AEs) will reported. AEs will be assessed by the treating physician using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.	Up to 12 weeks

Collaborators and Investigators

• Sponsor: Aaron Wolfson
• Investigators: Principal Investigator: Aaron H Wolfson, MD, FACR, University of Miami

Study record dates

Study Major Dates

• Study Start (Actual): April 15, 2023
• Primary Completion (Estimated): April 15, 2029
• Study Completion (Estimated): April 15, 2034

Study Registration Dates

• First Submitted: October 28, 2022
• First Submitted That Met QC Criteria: October 28, 2022
• First Posted (Actual): November 3, 2022

Study Record Updates

• Last Update Posted (Actual): August 3, 2026
• Last Update Submitted That Met QC Criteria: July 30, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Uterine Diseases; Genital Diseases, Female; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Therapeutics; Radiotherapy; pembrolizumab; Brachytherapy; lenvatinib
• Other Study ID Numbers: 20220813

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No